Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Visilizumab
(D06314)
[1] Visilizumab[1] Visilizumab (D06314) 💬[3] CD3D,
CD3E,
CD3G 💬
[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[2] 96, 97 💬
2Visilizumab (HuM291
(D06314)
[1] Visilizumab[1] Visilizumab (D06314) 💬[3] CD3D,
CD3E,
CD3G 💬
[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 97 💬
3Visilizumab (Nuvion)
(D06314)
[1] Visilizumab[1] Visilizumab (D06314) 💬[3] CD3D,
CD3E,
CD3G 💬
[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 97 💬
4Visilizumab (Nuvion®
(D06314)
[1] Visilizumab[1] Visilizumab (D06314) 💬[3] CD3D,
CD3E,
CD3G 💬
[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 97 💬